公开(公告)号：US11638831B2

公开(公告)日：2023-05-02

申请号：US16769895

申请日：2018-12-14

申请人： THE LONDON PSYCHIATRY CENTRE

发明人： Antonios Zamar

IPC分类号： A61P25/24 ,  A61N2/00 ,  A61B5/0245 ,  A61B5/00 ,  A61K31/198 ,  A61K31/554 ,  A61N2/02 ,  C12Q1/6883 ,  G01N33/78

摘要： The present invention relates to treatment of a psychiatric condition, for example resistant depression (RD), bipolar disorder (either threshold or sub-threshold) and/or major depressive disorder via application of repetitive transcranial magnetic stimulation with a drug treatment, in particular application of repetitive transcranial magnetic stimulation with treatment to modulate the activity of the neurones and induce neuroplasticity and the use of Thyroid hormone treatment to increase quantity or activity of thyroid hormones, for example for treatment of thyroid dysfunction. Patients may be selected for treatment by testing for the presence of normal thyroid function.

公开(公告)号：US20230087834A1

公开(公告)日：2023-03-23

申请号：US17932982

申请日：2022-09-16

申请人： THE GEORGE INSTITUTE FOR GLOBAL HEALTH

发明人： Anthony RODGERS ,  Stephen MacMAHON

IPC分类号： A61K31/4422 ,  A61P9/12 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/41 ,  A61K31/382 ,  A61K31/40 ,  A61K31/277 ,  A61K31/4178 ,  A61K31/517 ,  A61K31/4035 ,  A61K31/495 ,  A61K31/554 ,  A61K31/4418 ,  A61K31/549

摘要： Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

公开(公告)号：US11596640B2

公开(公告)日：2023-03-07

申请号：US17591588

申请日：2022-02-02

申请人： James Peter Morrissette

发明人： James Peter Morrissette

IPC分类号： A61K31/554 ,  A61K36/185 ,  A61K9/48

摘要： A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine, kava, and optionally, at least one of CDP Choline, and Alpha GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter.

公开(公告)号：US20230068969A1

公开(公告)日：2023-03-02

申请号：US17897503

申请日：2022-08-29

申请人： Assa Weinberg

发明人： Assa Weinberg

IPC分类号： A61K31/4422 ,  A61P27/02 ,  A61K31/04 ,  A61K31/138 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/216 ,  A61K31/277 ,  A61K31/345 ,  A61K31/401 ,  A61K31/403 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/472 ,  A61K31/50 ,  A61K31/517 ,  A61K31/549 ,  A61K31/55 ,  A61K31/554 ,  A61K31/675

摘要： A method is provided to prevent and to treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered by ophthalmic preparation directly onto or into the eye where Macular Degeneration is formed, to increase the capillary network and blood supply to the retinal macula.

公开(公告)号：US11590144B2

公开(公告)日：2023-02-28

申请号：US17697333

申请日：2022-03-17

申请人： James Peter Morrissette

发明人： James Peter Morrissette

IPC分类号： A61K31/554 ,  A61K36/185 ,  A61K9/48

摘要： A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine and GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter.

公开(公告)号：US11583539B2

公开(公告)日：2023-02-21

申请号：US17548090

申请日：2021-12-10

申请人： ALBIREO AB

发明人： Per-Göran Gillberg ,  Jan Mattsson ,  Pat Horn ,  Paresh Soni

IPC分类号： A61K31/554 ,  A61P1/16 ,  A61K9/16

摘要： Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

公开(公告)号：US11534409B2

公开(公告)日：2022-12-27

申请号：US17559158

申请日：2021-12-22

申请人： CLEXIO BIOSCIENCES LTD.

发明人： Dinesh K. Haswani ,  Derek V. Moe ,  Victoria A. O'Neill ,  Randal A. Seburg ,  Manuel A. Vega Zepeda

IPC分类号： A61K9/50 ,  A61K9/28 ,  A61K45/06 ,  A61K31/4458 ,  A61K47/58 ,  A61K31/00 ,  A61K9/20 ,  A61K31/136 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/437 ,  A61K31/485 ,  A61K31/515 ,  A61K31/5513 ,  A61K31/554 ,  A61K47/61 ,  A61K47/54 ,  A61K47/59 ,  A61K9/00 ,  A61K31/135

摘要： Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

公开(公告)号：US11504382B2

公开(公告)日：2022-11-22

申请号：US17267693

申请日：2019-08-09

申请人： Antios Therapeutics, Inc.

发明人： Raffaele De Francesco ,  Lorena Donnici ,  Luca Guidotti ,  Matteo Iannacone ,  Romano Di Fabio ,  Vincenzo Summa ,  Adolfo Prandi ,  Pietro Randazzo ,  Davide Gornati ,  Alessandro Grillo ,  Luca Ferrante ,  Leda Ivanova Bencheva ,  Marilenia De Matteo ,  Marco Ferrara

IPC分类号： A61P31/20 ,  C07D513/14 ,  C07D515/08 ,  C07D515/14 ,  C07D519/00 ,  A61K31/554 ,  A61K31/407

摘要： The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

公开(公告)号：US11426415B2

公开(公告)日：2022-08-30

申请号：US16491826

申请日：2018-03-06

申请人： Washington University ,  The United States of America, As Represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

发明人： Fumihiko Urano ,  Jana Mahadevan ,  Amy Clark ,  Ajit Jadhav ,  David Maloney ,  Brandon Harvey ,  Shyh-ming Yang ,  Mark Henderson

IPC分类号： A61K31/554 ,  A61K9/00 ,  A61K31/155 ,  A61K31/4178 ,  A61K31/4985 ,  A61K45/06 ,  C07K14/605

摘要： The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.

公开(公告)号：US11426366B2

公开(公告)日：2022-08-30

申请号：US15574346

申请日：2016-05-12

申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

发明人： Scott Sherman ,  Torsten Falk ,  Miguel Estevez

IPC分类号： A61P25/26 ,  A61K31/135 ,  A61K31/166 ,  A61K31/198 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/553 ,  A61K31/554 ,  A61K31/5415 ,  A61K31/4439 ,  A61P25/16

摘要： This invention provides methods utilizing ketamine for the treatment of motor disorders and/or side effects associated with certain medications used in the treatment of motor disorders. For example, in some embodiments, methods are provided for treating side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of ketamine or a pharmaceutically acceptable salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with motor disorder (e.g., Parkinson's disease) treatments, and effective doses of ketamine or a pharmaceutically acceptable salt thereof.